Listing 1 - 10 of 20 | << page >> |
Sort by
|
Choose an application
In the early decades since the introduction in the early '80s of immunoglobulin therapy many studies tried to identify which clinical indications might benefit from the therapy, which treatment’s schedules are effective and safe. It is universally accepted that immunoglobulin therapy is a life-saving treatment in patients with PID. The rise of new indications for further different clinical conditions resulted in a steady increase in demand for immunoglobulins. Currently the consumption of immunoglobulin for PID represents a small fraction of the market. In the recent past we have been observing: 1) An increase in the demand for plasma and in the consequent need to increase the number of donors; 2) Changes in methods to improve IgG recovery and to increase productivity as a response to growing clinical demand; 3) Introduction of immunoglobulin treatments with higher concentration; 4) Changes in the timing of administration with an increase in the rate of infusion; 5) Introduction of immunoglobulin treatment administered subcutaneously mainly confined initially to patients with PID and later extended to other clinical indications which often require higher volumes of infusion. Doctors following patients with PID were initially alarmed only to a possible risk of shortage. More relevant and less discussed appear the possible consequences of: 1) the risk of an improper transfer of information on treatments from a clinical indication to another. In particular, the idea of a mere replacement function in patients with PID might possibly be borrowed from the model of other clinical conditions requiring a replacement such as haemophilia. In PID, immunoglobulin treatment instead is obviously replacing a missing feature. However, other immune alterations are responsible for the large number of PID-associated diseases including inflammatory manifestations and tumors, common causes of morbidity and mortality. The immunomodulatory effects of immunoglobulin administered at replacement dosages on multiple cells and immune system functions are still largely to be checked in in vitro studies and in vivo. 2) the changes in the immunoglobulin production and schedules of administration. These should have been assessed in studies of drug surveillance, necessary in order to evaluate on large numbers of what it is initially reported on patients enrolled in the pivotal clinical trials, usually in the absence of most of the main disease-associated clinical conditions affecting pharmacokinetics, efficacy and tolerability. Severe side effects are now more frequently reported. This requires surveillance studies in order to verify the tolerability. Nowadays, personalized health research presents methodologic challenges, since emphasis is placed on the individual response rather than on the population. Even within a universally accepted indication, such as in PID, the identification of prognostic markers should guide the therapeutic intervention. 3) the risk of a decrease in the surveillance and monitoring of PID-associated clinical conditions. In fact, self- administration of immunoglobulins administered subcutaneously increased the independence of a number of patients. On the other hand, it led to the reduction in the number of contacts between specialized centers and patients who often require a close monitoring of disease-associated conditions. A wide debate between experts is necessary to afford the new challenge on immunoglobulin usage.
Immunedeficienc --- Manufacture --- adverse events --- Personalised treatment --- Immunoglobulin Therapy --- Mechanism
Choose an application
In the early decades since the introduction in the early '80s of immunoglobulin therapy many studies tried to identify which clinical indications might benefit from the therapy, which treatment’s schedules are effective and safe. It is universally accepted that immunoglobulin therapy is a life-saving treatment in patients with PID. The rise of new indications for further different clinical conditions resulted in a steady increase in demand for immunoglobulins. Currently the consumption of immunoglobulin for PID represents a small fraction of the market. In the recent past we have been observing: 1) An increase in the demand for plasma and in the consequent need to increase the number of donors; 2) Changes in methods to improve IgG recovery and to increase productivity as a response to growing clinical demand; 3) Introduction of immunoglobulin treatments with higher concentration; 4) Changes in the timing of administration with an increase in the rate of infusion; 5) Introduction of immunoglobulin treatment administered subcutaneously mainly confined initially to patients with PID and later extended to other clinical indications which often require higher volumes of infusion. Doctors following patients with PID were initially alarmed only to a possible risk of shortage. More relevant and less discussed appear the possible consequences of: 1) the risk of an improper transfer of information on treatments from a clinical indication to another. In particular, the idea of a mere replacement function in patients with PID might possibly be borrowed from the model of other clinical conditions requiring a replacement such as haemophilia. In PID, immunoglobulin treatment instead is obviously replacing a missing feature. However, other immune alterations are responsible for the large number of PID-associated diseases including inflammatory manifestations and tumors, common causes of morbidity and mortality. The immunomodulatory effects of immunoglobulin administered at replacement dosages on multiple cells and immune system functions are still largely to be checked in in vitro studies and in vivo. 2) the changes in the immunoglobulin production and schedules of administration. These should have been assessed in studies of drug surveillance, necessary in order to evaluate on large numbers of what it is initially reported on patients enrolled in the pivotal clinical trials, usually in the absence of most of the main disease-associated clinical conditions affecting pharmacokinetics, efficacy and tolerability. Severe side effects are now more frequently reported. This requires surveillance studies in order to verify the tolerability. Nowadays, personalized health research presents methodologic challenges, since emphasis is placed on the individual response rather than on the population. Even within a universally accepted indication, such as in PID, the identification of prognostic markers should guide the therapeutic intervention. 3) the risk of a decrease in the surveillance and monitoring of PID-associated clinical conditions. In fact, self- administration of immunoglobulins administered subcutaneously increased the independence of a number of patients. On the other hand, it led to the reduction in the number of contacts between specialized centers and patients who often require a close monitoring of disease-associated conditions. A wide debate between experts is necessary to afford the new challenge on immunoglobulin usage.
Immunedeficienc --- Manufacture --- adverse events --- Personalised treatment --- Immunoglobulin Therapy --- Mechanism
Choose an application
In the early decades since the introduction in the early '80s of immunoglobulin therapy many studies tried to identify which clinical indications might benefit from the therapy, which treatment’s schedules are effective and safe. It is universally accepted that immunoglobulin therapy is a life-saving treatment in patients with PID. The rise of new indications for further different clinical conditions resulted in a steady increase in demand for immunoglobulins. Currently the consumption of immunoglobulin for PID represents a small fraction of the market. In the recent past we have been observing: 1) An increase in the demand for plasma and in the consequent need to increase the number of donors; 2) Changes in methods to improve IgG recovery and to increase productivity as a response to growing clinical demand; 3) Introduction of immunoglobulin treatments with higher concentration; 4) Changes in the timing of administration with an increase in the rate of infusion; 5) Introduction of immunoglobulin treatment administered subcutaneously mainly confined initially to patients with PID and later extended to other clinical indications which often require higher volumes of infusion. Doctors following patients with PID were initially alarmed only to a possible risk of shortage. More relevant and less discussed appear the possible consequences of: 1) the risk of an improper transfer of information on treatments from a clinical indication to another. In particular, the idea of a mere replacement function in patients with PID might possibly be borrowed from the model of other clinical conditions requiring a replacement such as haemophilia. In PID, immunoglobulin treatment instead is obviously replacing a missing feature. However, other immune alterations are responsible for the large number of PID-associated diseases including inflammatory manifestations and tumors, common causes of morbidity and mortality. The immunomodulatory effects of immunoglobulin administered at replacement dosages on multiple cells and immune system functions are still largely to be checked in in vitro studies and in vivo. 2) the changes in the immunoglobulin production and schedules of administration. These should have been assessed in studies of drug surveillance, necessary in order to evaluate on large numbers of what it is initially reported on patients enrolled in the pivotal clinical trials, usually in the absence of most of the main disease-associated clinical conditions affecting pharmacokinetics, efficacy and tolerability. Severe side effects are now more frequently reported. This requires surveillance studies in order to verify the tolerability. Nowadays, personalized health research presents methodologic challenges, since emphasis is placed on the individual response rather than on the population. Even within a universally accepted indication, such as in PID, the identification of prognostic markers should guide the therapeutic intervention. 3) the risk of a decrease in the surveillance and monitoring of PID-associated clinical conditions. In fact, self- administration of immunoglobulins administered subcutaneously increased the independence of a number of patients. On the other hand, it led to the reduction in the number of contacts between specialized centers and patients who often require a close monitoring of disease-associated conditions. A wide debate between experts is necessary to afford the new challenge on immunoglobulin usage.
Immunedeficienc --- Manufacture --- adverse events --- Personalised treatment --- Immunoglobulin Therapy --- Mechanism
Choose an application
Contenu : Les mutilations génitales féminines (MGF) sont un réel problème de santé publique et sont globalement reconnues comme une violation des droits humains. Selon le dernier rapport de l’UNICEF (2016), plus de 200 millions de filles et de femmes vivant dans au moins 30 pays d’Afrique, du Moyen-Orient, et d’Asie auraient subi une forme de MGF. L’organisation mondiale de la santé (OMS) définit les mutilations génitales féminines comme étant toutes les interventions aboutissant à une ablation partielle ou totale des organes génitaux externes de la femme ou toute autre lésion des organes génitaux féminins pratiquée à des fins non thérapeutiques (WHO, 2008). En Wallonie et à Bruxelles, plus de 300 filles naissent d’une maman excisée et sont potentiellement à risque d’être excisées à leur tour s’il n’y a pas de travail de prévention (Stratégies concertées MGF). En Belgique, les mesures préventives et de protection mises en œuvre par les associations spécialisées dans la lutte contre les MGF ont induit chez certaines femmes une prise de conscience des méfaits de cette pratique. Méthodes : Il s’agit d’une étude descriptive qui repose sur l’analyse thématique de la méthode qualitative basée sur les entretiens. Les entretiens ont été réalisés auprès des mères d’origine subsaharienne victimes de MGF passe par le silence et évitement, l’adaptation, la confrontation et la sensibilisation. La majorité des participantes ont eu le soutien de leur mari de culture différente et la loi pour convaincre et sensibiliser leurs proches. Conclusion : les stratégies mises en œuvre par les participantes ont été le fruit d’une recherche personnelle. La plupart d’entre elles ont choisi des mesures strictes voire sacrées comme par exemple une rupture communautaire ou un exil permanent. Cependant, une minorité des participantes ont préféré des mesures souples tout en gardant à l’esprit de maintenir la décision.
Choose an application
Dans ce récit poignant et inspirant, Catherine Gildiner brosse le portrait émouvant de cinq de ses patients les plus mémorables. De Peter le musicien brillant souffrant de troubles sexuels, à Laura la jeune femme abandonnée par son père dans une cabane isolée pendant son enfance, en passant par Danny l’Autochtone qui a énormément souffert dans un pensionnat, ou encore par Alana la jeune femme torturée par son père dès son plus jeune âge, et Madeline, véritable bourreau de travail dont la mère négligente lui disait chaque matin « Bonjour le monstre »… Ils sont tous parvenus à surmonter un immense traumatisme et à résoudre leurs problèmes personnels. Chacun est l’expression même de l’introspection, de la persévérance et du pardon dans sa lutte pour affronter la vérité aux côtés d'une professionnelle pétrie d'humanité. Et si, en plus de vous attachez profondément à ces personnes, vous vous surpreniez à travailler sur vous ?
Choose an application
This concise book serves as a practical primer for the care of patients with primary brain tumors. Divided into two major sections, the first provides chapters with key information for each major brain tumor type. This includes basic information about etiology, epidemiology, clinical features, pathology, imaging, diagnostic workup, and treatment. The second section of the book features chapters that delve into supportive care management with specifics about management for each of the major conditions. This includes tumor-related epilepsy, venous thromboembolism in brain tumor patients, and corticosteroid management and toxicity. Detailed and clinically-focused information about chemotherapy regimens, dosing, monitoring, management of toxicities and patient education are also provided. Brain Tumors is a quick resource in the inpatient setting or in the clinic and educational resource to help new providers in the neuro-oncology field with the accumulated knowledge of clinicians with practical experience. .
Neurology. --- Internal medicine. --- Internal Medicine. --- Brain Neoplasms. --- Antineoplastic Agents. --- Drug-Related Side Effects and Adverse Reactions --- Radiotherapy --- adverse events. --- Brain --- Tumors.
Choose an application
This open access book provides a concise yet comprehensive overview on how to build a quality management program for hematopoietic stem cell transplantation (HSCT) and cellular therapy. The text reviews all the essential steps and elements necessary for establishing a quality management program and achieving accreditation in HSCT and cellular therapy. Specific areas of focus include document development and implementation, audits and validation, performance measurement, writing a quality management plan, the accreditation process, data management, and maintaining a quality management program. Written by experts in the field, Quality Management and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy: A Practical Guide is a valuable resource for physicians, healthcare professionals, and laboratory staff involved in the creation and maintenance of a state-of-the-art HSCT and cellular therapy program.
Haematology --- Oncology --- Hematology --- Blood Transfusion Medicine --- Internal Medicine --- outcome analysis --- structural indicators --- process indicators --- Hematopoietic Stem Cell Transplantation --- Quality Management --- Audits --- Qualification and Validation --- Personnel Requirements --- Performance Measurement --- Tracking and Traceability --- Adverse Events --- Quality Management Plan --- Accreditation --- Data Management --- Training --- Risk Management --- JACIE
Choose an application
Cancer remains one of the main causes of morbidity and mortality worldwide. Although many pharmacological and clinical advances have been made, there is a constant need for new molecules to improve the overall options for treatment. Natural compounds from animal, microbial, vegetal, or fungal origin represent countless sources of new compounds that can be used as anticancer drugs, provided their activity, bioavailability, and toxicity are adequate. This book aims to compile both original articles and reviews that cover the most recent advances in the use of natural compounds for cancer treatment, and provide new objectives and advice for future research in the field of biological activity of natural compounds.
microbiota --- treatment --- n/a --- sulforaphane --- synergy --- epigenetic --- natural compound --- xenohormesis --- anticancer --- miR-663 --- tyrosine kinase inhibitors --- acetylation --- epidemiology --- double-blinded --- inflammation --- bladder cancer --- polypharmacology --- animal model --- synbiotics --- resveratrol --- royal jelly --- 5-aza-2’-deoxycytine --- saponins --- phenolics --- cardiovascular disease --- antioxidant --- colorectal cancer --- trypsin inhibitors --- seeds --- green tea --- Gac --- randomized clinical trial --- melanoma --- adverse events --- extraction --- microbiome --- Momordica cochinchinensis --- freeze dried extract --- renal cell carcinoma --- methylation --- cancer --- probiotics --- 5-aza-2'-deoxycytine
Choose an application
Cardiology and cardiovascular sciences are two rapidly growing areas in medicine, with heart diseases being the number one cause of death worldwide. The last four decades have witnessed many developments in various cardiological sciences, including coronary artery disease, valve disease, heart failure, congenital heart diseases, and cardiovascular imaging, with a number of newly developed concepts, such as cardio-oncology, cardio-renal diseases, and preventive cardiology. This Special Issue (SI) of the Journal of Clinical Medicine, entitled “JCM-Advances in Cardiology”, focuses on recent advances in the cardiological sciences. It published 8 research articles of significant clinical and scientific value.
Medicine --- Pharmacology --- ST segment elevation myocardial infarction --- COVID-19 --- primary percutaneous intervention --- Coptic clergy --- mortality --- cardiovascular risk factors --- prevalence --- major adverse events --- obesity --- ACE2 --- renin–angiotensin system --- extraction --- reimplantation --- pacing --- ICD --- CRT --- dilated cardiomyopathy (DCM) --- LMNA --- lamin A --- lamin C --- next generation sequencing (NGS) --- myocarditis --- arrhythmias --- telemonitoring --- implantable cardioverter defibrillator --- implantable loop recorder --- Holter ECG --- metabolic-dysfunction-associated fatty liver disease (MAFLD) --- hepatic steatosis --- SteatoTest --- adipokines --- adiponectin --- visfatin --- cardiovascular disease --- n/a --- renin-angiotensin system
Choose an application
Cardiology and cardiovascular sciences are two rapidly growing areas in medicine, with heart diseases being the number one cause of death worldwide. The last four decades have witnessed many developments in various cardiological sciences, including coronary artery disease, valve disease, heart failure, congenital heart diseases, and cardiovascular imaging, with a number of newly developed concepts, such as cardio-oncology, cardio-renal diseases, and preventive cardiology. This Special Issue (SI) of the Journal of Clinical Medicine, entitled “JCM-Advances in Cardiology”, focuses on recent advances in the cardiological sciences. It published 8 research articles of significant clinical and scientific value.
Medicine --- Pharmacology --- ST segment elevation myocardial infarction --- COVID-19 --- primary percutaneous intervention --- Coptic clergy --- mortality --- cardiovascular risk factors --- prevalence --- major adverse events --- obesity --- ACE2 --- renin–angiotensin system --- extraction --- reimplantation --- pacing --- ICD --- CRT --- dilated cardiomyopathy (DCM) --- LMNA --- lamin A --- lamin C --- next generation sequencing (NGS) --- myocarditis --- arrhythmias --- telemonitoring --- implantable cardioverter defibrillator --- implantable loop recorder --- Holter ECG --- metabolic-dysfunction-associated fatty liver disease (MAFLD) --- hepatic steatosis --- SteatoTest --- adipokines --- adiponectin --- visfatin --- cardiovascular disease --- n/a --- renin-angiotensin system
Listing 1 - 10 of 20 | << page >> |
Sort by
|